X4 Pharmaceuticals, Inc. (XFOR)
| Previous close | 0.8967 |
| Open | 0.8800 |
| Bid | 0.9061 x 600 |
| Ask | 0.9210 x 800 |
| Day's range | 0.8800 - 0.9499 |
| 52-week range | 0.5720 - 2.5750 |
| Volume | |
| Avg. volume | 3,423,048 |
| Market cap | 153.73M |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript May 7, 2024 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.25884 EPS, expectations were $-0.17. X4 Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: [Indiscernible] X4 […]
- GuruFocus.com
X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
Discover how X4 Pharmaceuticals navigates challenges and capitalizes on new opportunities in its latest quarterly earnings call.
- Reuters
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. The decision is based on a late-stage study where the therapy showed 60% reduction in infection rate compared to placebo when tested in patients with WHIM syndrome.
